Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Up 6.3% – What’s Next?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT)’s stock price was up 6.3% on Wednesday . The company traded as high as $2.20 and last traded at $2.18. Approximately 200,542 shares were traded during mid-day trading, an increase of 9% from the average daily volume of 183,975 shares. The stock had previously closed at $2.05.

Analyst Ratings Changes

A number of research analysts recently commented on NAUT shares. Wall Street Zen upgraded shares of Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Nautilus Biotechnology currently has a consensus rating of “Sell” and an average price target of $2.50.

Nautilus Biotechnology Trading Up 6.3%

The stock has a market cap of $275.36 million, a price-to-earnings ratio of -4.36 and a beta of 1.49. The company has a fifty day simple moving average of $2.02 and a 200-day simple moving average of $1.29.

Nautilus Biotechnology (NASDAQ:NAUT) last released its earnings results on Monday, October 27th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. As a group, analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year.

Institutional Trading of Nautilus Biotechnology

Several large investors have recently added to or reduced their stakes in the company. Callan Family Office LLC purchased a new stake in shares of Nautilus Biotechnology in the second quarter valued at $35,000. Ashton Thomas Private Wealth LLC acquired a new position in Nautilus Biotechnology during the third quarter valued at $38,000. Qube Research & Technologies Ltd acquired a new position in Nautilus Biotechnology during the second quarter valued at $45,000. XTX Topco Ltd lifted its stake in Nautilus Biotechnology by 86.2% in the 2nd quarter. XTX Topco Ltd now owns 66,194 shares of the company’s stock worth $48,000 after acquiring an additional 30,641 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in Nautilus Biotechnology by 468.3% during the 1st quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock worth $51,000 after acquiring an additional 50,871 shares during the period. 50.71% of the stock is owned by institutional investors and hedge funds.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.